FDA ok's once-daily Kaletra for treatment-experienced HIV patients

The US FDA has approved once-daily dosing of Abbott's fixed-dose combination HIV antiretroviral drug Kaletra (lopinavir/ritonavir (Abbott's Norvir)) for use in treatment-experienced adult patients in combination with other antiretroviral products.

The US FDA has approved once-daily dosing of Abbott's fixed-dose combination HIV antiretroviral drug Kaletra (lopinavir/ritonavir (Abbott's Norvir)) for use in treatment-experienced adult patients in combination with other antiretroviral products.

This regimen has already been approved for treatment-naïve patients.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category